Bank Pictet & Cie Europe AG Cuts Position in Vaxcyte, Inc. (NASDAQ:PCVX)

Bank Pictet & Cie Europe AG lowered its holdings in shares of Vaxcyte, Inc. (NASDAQ:PCVX) by 2.3% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 3,805 shares of the company’s stock after selling 89 shares during the quarter. Bank Pictet & Cie Europe AG’s holdings in Vaxcyte were worth $435,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. Darwin Global Management Ltd. raised its stake in shares of Vaxcyte by 374.3% during the 1st quarter. Darwin Global Management Ltd. now owns 2,750,804 shares of the company’s stock worth $187,907,000 after buying an additional 2,170,845 shares during the period. Vanguard Group Inc. increased its stake in shares of Vaxcyte by 15.2% during the first quarter. Vanguard Group Inc. now owns 9,737,254 shares of the company’s stock worth $665,152,000 after purchasing an additional 1,284,883 shares in the last quarter. Capital Research Global Investors raised its position in shares of Vaxcyte by 20.4% during the 1st quarter. Capital Research Global Investors now owns 4,140,521 shares of the company’s stock worth $282,839,000 after purchasing an additional 700,414 shares during the last quarter. Janus Henderson Group PLC lifted its stake in Vaxcyte by 9.9% in the 1st quarter. Janus Henderson Group PLC now owns 7,673,868 shares of the company’s stock valued at $524,117,000 after buying an additional 692,492 shares in the last quarter. Finally, Avoro Capital Advisors LLC acquired a new stake in Vaxcyte in the 1st quarter worth about $39,278,000. 96.78% of the stock is owned by institutional investors and hedge funds.

Vaxcyte Trading Down 2.4 %

Shares of PCVX stock opened at $112.66 on Wednesday. Vaxcyte, Inc. has a twelve month low of $45.61 and a twelve month high of $121.06. The company’s 50-day moving average price is $104.02 and its 200-day moving average price is $83.43. The stock has a market cap of $12.57 billion, a price-to-earnings ratio of -24.07 and a beta of 0.99.

Vaxcyte (NASDAQ:PCVX) last posted its earnings results on Tuesday, August 6th. The company reported ($1.10) earnings per share for the quarter, beating the consensus estimate of ($1.14) by $0.04. During the same quarter last year, the business earned ($0.70) earnings per share. As a group, equities research analysts predict that Vaxcyte, Inc. will post -4.33 EPS for the current year.

Insider Activity at Vaxcyte

In related news, SVP Elvia Cowan sold 5,000 shares of the stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $107.67, for a total value of $538,350.00. Following the completion of the transaction, the senior vice president now directly owns 12,723 shares in the company, valued at approximately $1,369,885.41. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In related news, SVP Elvia Cowan sold 5,000 shares of the business’s stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $107.67, for a total value of $538,350.00. Following the sale, the senior vice president now directly owns 12,723 shares in the company, valued at approximately $1,369,885.41. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Andrew Guggenhime sold 8,000 shares of the stock in a transaction dated Wednesday, September 18th. The stock was sold at an average price of $115.94, for a total transaction of $927,520.00. Following the transaction, the chief financial officer now directly owns 90,383 shares of the company’s stock, valued at approximately $10,479,005.02. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 92,098 shares of company stock worth $9,937,773. Insiders own 3.10% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on PCVX. Jefferies Financial Group raised their target price on Vaxcyte from $108.00 to $129.00 and gave the company a “buy” rating in a research report on Tuesday, September 3rd. Mizuho lifted their target price on shares of Vaxcyte from $113.00 to $163.00 and gave the stock an “outperform” rating in a research note on Tuesday, September 10th. BTIG Research increased their target price on shares of Vaxcyte from $98.00 to $160.00 and gave the company a “buy” rating in a research report on Tuesday, September 3rd. Bank of America boosted their price target on shares of Vaxcyte from $101.00 to $140.00 and gave the stock a “buy” rating in a research report on Wednesday, September 4th. Finally, Needham & Company LLC increased their price objective on shares of Vaxcyte from $95.00 to $140.00 and gave the company a “buy” rating in a report on Tuesday, September 3rd. Seven research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Vaxcyte currently has an average rating of “Buy” and a consensus price target of $147.50.

Vaxcyte Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.